Bio-Techne Stock Surges 7.6%, With A 6-Day Winning Spree
Bio-Techne (TECH) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 7.6% return. The company has gained about $704 Mil in value over the last 6 days, with its current market capitalization at about $9.9 Bil. The stock remains 11.1% below its value at the end of 2024. This compares with year-to-date returns of 13.9% for the S&P 500.
TECH provides life science reagents, instruments, and diagnostic products for research, diagnostics, and cell and gene therapy applications. After this rally, is TECH still a buy – or is it time to lock in gains? Deep dive with Buy or Sell TECH.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. We go beyond just equities. Is a portfolio of 10% commodities, 10% gold, and 2% crypto in addition to equities and bonds likely to return more during the next 1-3 years, and protect you better if markets crash 20%? We have crunched the numbers.
Comparing TECH Stock Returns With The S&P 500
The following table summarizes the return for TECH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TECH | S&P 500 |
|---|---|---|
| 1D | 0.5% | -0.5% |
| 6D (Current Streak) | 7.6% | 0.8% |
| 1M (21D) | 20.5% | 0.6% |
| 3M (63D) | 9.3% | 5.3% |
| YTD 2025 | -11.1% | 13.9% |
| 2024 | -6.2% | 23.3% |
| 2023 | -6.5% | 24.2% |
| 2022 | -35.6% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 74 S&P constituents with 3 days or more of consecutive gains and 21 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 12 | 11 |
| 4D | 45 | 4 |
| 5D | 12 | 5 |
| 6D | 2 | 0 |
| 7D or more | 3 | 1 |
| Total >=3 D | 74 | 21 |
Key Financials for Bio-Techne (TECH)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $1.2 Bil | $1.2 Bil |
| Operating Income | $246.4 Mil | $242.8 Mil |
| Net Income | $168.1 Mil | $73.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $316.2 Mil | $317.0 Mil |
| Operating Income | $38.7 Mil | $116.7 Mil |
| Net Income | $22.6 Mil | $-17.7 Mil |
While TECH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.